Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants 

Related Keywords

United States ,America ,Whit Tingley ,Tenaya Therapeutics Inc ,Administration Of Inhibitors ,Heart Failure Society Of America ,Tenaya Therapeutics ,Failure Society ,Annual Scientific ,Chief Medical ,Demonstrate Safety ,Target Engagement ,Once Daily Dosin ,Highly Selective ,Shows Target Engagement ,Benefit Observed ,Additive Improvements ,Cardiac Structural ,Functional Measures ,